With several members receiving termination letters and its webpage archived, public health experts believe the days are ...

The CDC’s ACIP updated guidance on pneumococcal vaccination, recommending a single dose of PCV for all adults aged 50 years and older.

The Centers for Disease Control and Prevention might soon limit its guidance for who should receive a coronavirus booster ...

Penmenvy combines the antigenic components of Bexsero (meningococcal Group B vaccine) and Menveo (meningococcal Groups A, C, Y, and W-135 oligosaccharide diphtheria CRM197 conjugate vaccine).

Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

EPS estimates, maintains 2025 guidance, and targets $5.7 billion in cost savings through automation and R&D streamlining.

Thousands of Americans campaigning for the Novavax COVID-19 booster got some good news this week: the FDA signaled it might ...

Some key public health figures are taking an extraordinary step to try to shore up U.S. vaccination policy, feared to be ...

In his inaugural speech upon taking over as secretary of the Department of Health and Human Services, Robert F. Kennedy Jr.

Every year, during the last week of April, the world meets to observe World Immunization Week. This important initiative, led ...

Pfizer's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in ...